Compare MNDO & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MNDO | CUE |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 17.6M |
| IPO Year | 2000 | 2017 |
| Metric | MNDO | CUE |
|---|---|---|
| Price | $0.92 | $21.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 47.9K | ★ 965.7K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 20.95% | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.57 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $0.85 | $0.17 |
| 52 Week High | $1.50 | $41.42 |
| Indicator | MNDO | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 34.06 | 53.90 |
| Support Level | $0.89 | $0.30 |
| Resistance Level | $1.24 | $41.42 |
| Average True Range (ATR) | 0.04 | 4.04 |
| MACD | -0.00 | -1.89 |
| Stochastic Oscillator | 30.62 | 14.17 |
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.